Doconexent
Doconexent is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target free fatty acid receptor 1, transient receptor potential cation channel subfamily A member 1, retinoic acid receptor RXR-alpha, and potassium channel subfamily K member 10.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| animi-3 | unapproved drug other | 2013-02-06 |
| animi-3 with vitamin d | unapproved drug other | 2011-05-23 |
| bal-care dha | unapproved drug other | 2012-05-01 |
| bal-care dha essential | unapproved drug other | 2012-05-01 |
| bp vit 3 | unapproved drug other | 2025-02-13 |
| c-nate dha | unapproved drug other | 2024-01-22 |
| citranatal 90 dha | unapproved drug other | 2024-01-08 |
| citranatal assure | unapproved drug other | 2024-01-08 |
| citranatal bloom dha | unapproved drug other | 2020-04-06 |
| citranatal dha | unapproved drug other | 2020-07-28 |
Show 26 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
612 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | — | 1 | 1 | 2 | — | 3 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | 2 | 1 | 3 |
| Virus diseases | D014777 | — | B34 | — | — | — | 2 | — | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | — | 1 | — | 2 |
| Tick-borne encephalitis | D004675 | EFO_1001309 | A84 | — | — | — | 1 | — | 1 |
| Encephalitis | D004660 | — | — | — | — | — | 1 | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | 1 | — | 1 |
| Rabies | D011818 | — | A82 | — | — | — | 1 | — | 1 |
| Mitochondrial diseases | D028361 | EFO_0000591 | — | — | — | — | 1 | — | 1 |
| Mitral valve insufficiency | D008944 | — | — | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 1 | 1 | 1 | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | 1 | — | — | 2 |
| Vivax malaria | D016780 | EFO_0007445 | B51 | 1 | — | 1 | — | — | 2 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 1 | 1 | — | — | 2 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 1 | 1 | 1 | — | — | 2 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | — | — | 1 |
| Mucinous adenocarcinoma | D002288 | — | — | — | 1 | 1 | — | — | 1 |
| Ductal carcinoma breast | D018270 | — | — | — | 1 | 1 | — | — | 1 |
| Inflammatory breast neoplasms | D058922 | — | — | — | 1 | 1 | — | — | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | 3 | — | — | — | 3 |
| Uterine cervical neoplasms | D002583 | — | — | 1 | 1 | — | — | — | 2 |
| Depression | D003863 | — | F33.9 | — | 1 | — | — | 1 | 2 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 2 | — | — | — | 2 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 2 | 2 | — | — | — | 2 |
| Blood protein disorders | D001796 | — | — | 2 | 2 | — | — | — | 2 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 2 | — | — | — | 2 |
| Paraproteinemias | D010265 | — | D47.2 | 2 | 2 | — | — | — | 2 |
| Corneal diseases | D003316 | — | H18.9 | 2 | 2 | — | — | — | 2 |
| Drug resistance | D004351 | — | Z16.30 | 1 | 1 | — | — | — | 1 |
Show 20 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | 1 | — | — | — | — | 1 |
| Psychomotor agitation | D011595 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 1 | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | — | 1 | 1 |
| Fatty liver | D005234 | EFO_0003934 | — | — | — | — | — | 1 | 1 |
| Wasting syndrome | D019282 | — | — | — | — | — | — | 1 | 1 |
| Cachexia | D002100 | — | R64 | — | — | — | — | 1 | 1 |
| Nasal polyps | D009298 | — | J33 | — | — | — | — | 1 | 1 |
| Polyps | D011127 | EFO_0000662 | — | — | — | — | — | 1 | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Cytomegalovirus infections | D003586 | EFO_0001062 | B25 | — | — | — | — | 1 | 1 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Doconexent |
| INN | doconexent |
| Description | All-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a docosahexaenoic acid having six cis-double bonds at positions 4, 7, 10, 13, 16 and 19. It has a role as a nutraceutical, an antineoplastic agent, a human metabolite, a Daphnia tenebrosa metabolite, a mouse metabolite and an algal metabolite. It is a docosahexaenoic acid and an omega-3 fatty acid. It is a conjugate acid of a (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 6217-54-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL367149 |
| ChEBI ID | 28125 |
| PubChem CID | 445580 |
| DrugBank | DB03756 |
| UNII ID | ZAD9OKH9JC (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNK10
KCNK10
Organism
Homo sapiens
Gene name
KCNK10
Gene synonyms
TREK2
NCBI Gene ID
Protein name
potassium channel subfamily K member 10
Protein synonyms
2P domain potassium channel TREK2, Outward rectifying potassium channel protein TREK-2, potassium channel TREK-2, potassium channel, subfamily K, member 10, potassium channel, two pore domain subfamily K, member 10, protein phosphatase 1, regulatory subunit 97, TREK-2 K(+) channel subunit, TWIK-related K+ channel 2
Uniprot ID
Mouse ortholog
Kcnk10 (72258)
potassium channel subfamily K member 10 (F6YU65)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 191,190 documents
View more details
Safety
Black-box Warning
Black-box warning for: Citranatal 90 dha, Citranatal assure, Citranatal dha, Citranatal essence, Citranatal harmony, Citranatal harmony 2.1, Citranatal harmony 3.0, Citranatal medley, Nestabs dha, Nestabs one, Pnv-dha, Pnv-omega, Pre-tabs dha, Prenatal plus multivitamin plus dha minicaps, Prenate dha, Prenate enhance, Prenate essential, Prenate mini, Prenate restore, Primacare, Reaphirm plant source dha, Select-ob plus dha, Tristart dha, Vitafol, Vitafol fe plus, Vitafol-ob plus dha
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,776 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use